LGD4033-and-Its-Metabolites-in-the-Human-Body-v
Ligand Pharmaceuticals’ (Ligand) LGD-4033 is a selective androgen receptor modulator, or SARM. It is currently in clinical trials as a potential pharmaceutical treatment for muscle wasting and weakness associated with cancer, chronic diseases, and aging. It has also been found to enhance muscle strength in individuals recovering from injury and surgery. As a result, it has become popular among athletes and bodybuilders who seek to increase their performance without the side effects of traditional anabolic steroids. However, long-term use of SARMs is not well understood and may have adverse health consequences, including liver damage.
Although research on LGD-4033 is still in the early stages, studies have already shown that the drug increases lean body mass (LBM) in healthy individuals. In addition, it is known to have anti-inflammatory properties and inhibits the growth of tumors in mice. LGD-4033’s mechanism of action differs from that of steroidal androgens, which stimulate the prostate gland and cause unwanted side effects such as acne, increased blood pressure, and elevated cholesterol levels.
The drug is also being explored as a treatment for bone-related conditions such as osteoporosis, which is characterized by reduced bone density. It is thought to promote bone formation by binding to androgen receptors in bone cells, but without affecting the skeletal muscles.
LGD-4033 has also been shown to increase the size and number of muscle fibers in hypogonadal rats, a condition that is a precursor to osteoporosis. These changes are attributed to the drug’s partial androgenic activity, which is less potent than the full agonist activity of steroid drugs. Additionally, LGD-4033 has been shown to reduce lgd sarms and increase libido in hypogonadal males.
Due to the positive results of these studies, researchers have studied LGD-4033 and its metabolites to gain a better understanding of how the drug works in the human body. They have found that the elimination and excretion patterns of the drug are similar to those of other SARMs. In addition, they have identified the metabolites that are most commonly excreted in the urine.
These findings have been published in the journal Molecules. The authors analyzed urine samples from healthy volunteers that had taken a supplement containing LGD-4033. The samples were collected for up to 21 days and analyzed with liquid chromatography-high resolution mass spectrometry in negative ionization mode. The ratios of the two isomeric metabolites, M5-a and M5-b, were determined for each sample and used to calculate an estimate of time since LGD-4033 ingestion.
The authors also observed that the metabolite ratios in hydrolyzed samples changed over time, which indicates that the metabolites are being diluted as the LGD-4033 is eliminated from the body. This is expected because most SARMs are excreted in multiple isomeric forms, and a specific ratio can be used to estimate the amount of LGD-4033 that was ingested and subsequently metabolized. The authors hope that this information will contribute to best-practice analytical methods for the control of LGD-4033 in routine urine samples.
